Acquisition centres on Yupelri COPD franchise while retaining upside through respiratory and legacy pipeline assets.

Merck KGaA has agreed to acquire US-based life sciences company Bio-Techne, significantly expanding its presence across the life sciences value chain.

Biogen has agreed to acquire RayThera in a deal worth up to $1 billion, strengthening its position in immunology and adding a portfolio of small-molecule anti-inflammatory candidates to its development pipeline.

ResMed has completed its $340m acquisition of Noctrix Health, adding a newly approved neurostimulation therapy for restless leg syndrome (RLS) to its growing sleep medicine portfolio.

The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance.

The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure.

The combination forms one of the largest dedicated healthcare investors globally, spanning pharma, medtech, diagnostics, and healthcare infrastructure across three continents.

Deal strengthens Bayer’s position in retinal disease and glaucoma as long-acting ophthalmology therapies attract growing investment.

A strategic move into bispecific antibodies as pharma races to redefine autoimmune treatment through targeted immune cell depletion and next-generation T cell engagers

Securing a next-generation JAK2 inhibitor strengthens Lilly’s position in rare blood cancers as pharma accelerates investment in mechanism-driven oncology assets.

Deal highlights accelerating pharma shift into rare metabolic disorders and obesity-adjacent indications as companies hunt for de-risked, high-value assets.

Merit Medical Systems has acquired View Point Medical through a merger aimed at strengthening its interventional solutions business and broadening its medical device portfolio.